Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents
Results From the TAXUS-IV Trial
Duane S. Pinto, MD, FACC*,*,
Gregg W. Stone, MD, FACC
,
Stephen G. Ellis, MD, FACC
,
David A. Cox, MD, FACC
,
James Hermiller, MD, FACC||,
Charles OShaughnessy, MD, FACC¶,
J. Tift Mann, MD, FACC#,
Roxana Mehran, MD, FACC
,
Yingbo Na, MSc
,
Mark Turco, MD, FACC**,
Ronald Caputo, MD, FACC
,
Jeffrey J. Popma, MD, FACC
,
Donald E. Cutlip, MD, FACC*,
Mary E. Russell, MD, FACC
,
David J. Cohen, MD, MSc* for the TAXUS-IV Investigators
* Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York
Cleveland Clinic Foundation, Cleveland, Ohio
Mid Carolina Cardiology, Charlotte, North Carolina
|| St. Vincents Hospital, Indianapolis, Indiana
¶ Elyria Memorial Hospital, Elyria, Ohio
# WakeMed, Raleigh, North Carolina
** Washington Adventist Hospital, Tacoma Park, Maryland

St. Josephs Hospital, Syracuse, New York

Brigham and Womens Hospital, Boston, Massachusetts

Boston Scientific Corporation, Natick, Massachusetts

View larger version (15K):
[in a new window]
|
Figure 1 Curves showing freedom from target vessel revascularization at 1 year among patients assigned to clinical follow-up alone (A) or to mandatory 9-month angiographic follow-up (B). Events are summarized as unadjusted Kaplan-Meier estimates and comparisons between the groups were made with a log-rank test.
|
|
Copyright © 2006 by the American College of Cardiology Foundation.